Our translational research program focuses on a comparative approach, utilizing immunologically intact, canine patients with spontaneous cancer.This comparative approach provides a unique opportunity to evaluate the safety and effectiveness of next generation immunotherapies in a parallel canine patient population that presents the same challenges to effective immunotherapy as seen in human patients.The aim of this approach is to accelerate the translation of the most promising pre-clinical discoveries into the human clinic. Our lab is actively involved in developing the canine “model” for evaluating CART cell therapies.We have successfully translated several promising strategies to generate anti-tumor immunity from the lab and pre-clinical murine models into client owned dogs suffering from lymphoma, osteosarcoma and hemangiosarcoma.